Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 124.0% from a year ago
Total assets stood at $747.68M at the end of Q1 FY2026, up 124.0% from a year earlier and up 94.9% from the prior quarter. Over 3 fiscal years it compounded at +72.6% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +124.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 383.64M USD
- Year-over-year change
- +3.7%
- 3-year CAGR
- +72.6%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 383.64M | +3.7% |
| FY2024 | 2024-12-31 | 369.97M | +442.6% |
| FY2023 | 2023-12-31 | 68.18M | -8.6% |
| FY2022 | 2022-12-31 | 74.58M | — |
Total Assets vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total assets of $747.68M is the 2nd highest of the 8 companies compared; the peer median is $262.89M.
- Its year-over-year change of +124.0% is the highest of 7, against a peer median of -6.5%.
- Over three fiscal years its annual growth of +72.6% compares with a peer median of -0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | $760.97M | +30.5% | +33.1% | |
| Mar 2026 | $747.68M | +124.0% | +72.6% | |
UPBUpstream Bio, Inc. | Mar 2026 | $318.05M | -30.3% | +167.5% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $290.58M | — | — |
| Mar 2026 | $262.89M | -13.2% | -0.9% | |
| Mar 2026 | $198.72M | +0.3% | -14.3% | |
| Mar 2026 | $63.68M | -19.5% | +0.0% | |
| Dec 2025 | $11.5M | +1.9% | -24.3% | |
| Peer median (excluding ZBIO) | $262.89M | -6.5% | -0.4% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.